MedTrace Logo

An Exploratory Clinical Trial in Early Stage Huntington's Disease Patients With SEN0014196

NCT01485952 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 55

Last updated 2015-11-25

No results posted yet for this study

Summary

The primary objective of this study is to provide biological samples from patients with Huntington's disease to allow characterisation of the pharmacological mechanism of action of SEN0014196.

Conditions

  • Huntington Disease

Interventions

DRUG

SEN0014196 (Low Dose)

10 mg once daily administration (immediate release capsule)

DRUG

SEN0014196 (High Dose)

100 mg once daily administration (immediate release capsule)

DRUG

Placebo

Once daily administration (immediate release capsule)

Sponsors & Collaborators

  • Seventh Framework Programme

    collaborator OTHER

  • European Huntington's Disease Network

    collaborator NETWORK

  • Siena Biotech S.p.A.

    lead INDUSTRY

Principal Investigators

  • Bernhard G Landwehrmeyer, MD, PhD · European Huntington's Disease Network

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-03-31
Primary Completion
2011-11-30
Completion
2011-11-30

Countries

  • Germany

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01485952 on ClinicalTrials.gov